학술논문
INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
Document Type
Article
Author
Mellinghoff, Ingo K.; Van Den Bent, Martin J.; Blumenthal, Deborah T.; Touat, Mehdi; Peters, Katherine B.; Clarke, Jennifer Leigh; Mendez, Joe Sammy; Welsh, Liam; Mason, Warren P.; Hottinger, Andreas Felix; Sepulveda Sanchez, Juan Manuel; Wick, Wolfgang; Soffietti, Riccardo; Schoenfeld, Steven; Zhao, Dan; Pandya, Shuchi Sumant; Steelman, Lori; Hassan, Islam; Wen, Patrick Y.; Cloughesy, Timothy Francis
Source
Journal of Clinical Oncology; 6/10/2023 Supplement17, Vol. 41, pLBA1-LBA1, 1p
Subject
Language
ISSN
0732183X